Protein Helps Neurons Maintain Dopamine Production in Models of Parkinson's Disease
|
By LabMedica International staff writers Posted on 20 Oct 2016 |

Image: Diagram shows how the neuropeptide Prokineticin-2 (PK2) is rapidly induced during early stages of neurotoxic stress and secreted into extracellular spaces. PK2 is thought to act as a protective mechanism that helps neurons cope with Parkinson’s disease (Photo courtesy of Dr. Anumantha Kanthasamy, Iowa State University).
A team of neurodegenerative disease researchers has identified a protein that seems to help neurons in the brain maintain dopamine production.
Investigators at Iowa State University (Ames, USA) have been studying Prokineticin-2 (PK2), a recently discovered secreted protein that regulates important physiological functions including olfactory biogenesis and circadian rhythms in the central nervous system.
They reported in the October 5, 2016, online edition of the journal Nature Communications that although in mouse models PK2 expression was low in the nigral system of the brain, its receptors were constitutively expressed on nigrostriatal neurons, and that PK2 expression was highly induced in nigral dopaminergic neurons during early stages of degeneration in multiple mouse models of Parkinson’s disease (PD).
Functional studies demonstrated that PK2 promoted mitochondrial biogenesis and activated ERK (Extracellular signal-regulated kinase) and Akt (Protein kinase B) survival signaling pathways, thereby driving neuroprotection. Importantly, PK2 overexpression was protective, whereas PK2 receptor antagonism exacerbated dopaminergic degeneration in experimental PD.
PK2 signaling protected against oxidative stress, mitochondrial dysfunction, and dopaminergic degeneration. Blocking PK2 signaling using a PK2 receptor antagonist increased dopaminergic degeneration in a PD mouse model, while overexpression of PK2 by adeno-associated virus (AAV) gene delivery was neuroprotective. PK2 expression was also found to be elevated in the substantia nigra (SN) of PD patients, corroborating PK2’s clinical relevance in human PD.
“Of the thousands and thousands of factors we tracked in our experiments, why was this protein expressed so highly?” said senior author Dr. Anumantha Kanthasamy, professor of veterinary medicine at Iowa State University. “The neurons use PK2 to cope with stress. It is an in-built protective mechanism.”
Related Links:
Iowa State University
Investigators at Iowa State University (Ames, USA) have been studying Prokineticin-2 (PK2), a recently discovered secreted protein that regulates important physiological functions including olfactory biogenesis and circadian rhythms in the central nervous system.
They reported in the October 5, 2016, online edition of the journal Nature Communications that although in mouse models PK2 expression was low in the nigral system of the brain, its receptors were constitutively expressed on nigrostriatal neurons, and that PK2 expression was highly induced in nigral dopaminergic neurons during early stages of degeneration in multiple mouse models of Parkinson’s disease (PD).
Functional studies demonstrated that PK2 promoted mitochondrial biogenesis and activated ERK (Extracellular signal-regulated kinase) and Akt (Protein kinase B) survival signaling pathways, thereby driving neuroprotection. Importantly, PK2 overexpression was protective, whereas PK2 receptor antagonism exacerbated dopaminergic degeneration in experimental PD.
PK2 signaling protected against oxidative stress, mitochondrial dysfunction, and dopaminergic degeneration. Blocking PK2 signaling using a PK2 receptor antagonist increased dopaminergic degeneration in a PD mouse model, while overexpression of PK2 by adeno-associated virus (AAV) gene delivery was neuroprotective. PK2 expression was also found to be elevated in the substantia nigra (SN) of PD patients, corroborating PK2’s clinical relevance in human PD.
“Of the thousands and thousands of factors we tracked in our experiments, why was this protein expressed so highly?” said senior author Dr. Anumantha Kanthasamy, professor of veterinary medicine at Iowa State University. “The neurons use PK2 to cope with stress. It is an in-built protective mechanism.”
Related Links:
Iowa State University
Latest BioResearch News
- Immune Biomarkers Support Early Risk Stratification in Oral Precancer
- Global Genetic Map Identifies Regional Parkinson’s Variants to Support Diagnostics
- Breakthrough Genetic Map Advances Understanding of Bone Disorders
- Study Identifies Hereditary Subtype of Aggressive Prostate Cancer
- Gene Variants Linked to Pollution-Exacerbated Asthma
- Single-Cell Analysis Mapping Links Inflammation Response to Acute Myeloid Leukemia
- Study Reveals New Insights into Rare Blood Cancer Development
- New Findings Clarify Molecular Drivers of Rare Small Intestinal Cancer
- Lung Cancer Study Reveals Cellular Program Behind Therapy Resistance
- Tumor Genome Marker May Predict Treatment Benefit in Pediatric Cancers
- Lysosomal Gene Defect Linked to Severe Childhood Brain Disorders
- Genetic Testing Identifies Greater Inherited Sudden Cardiac Arrest Risk in Younger Individuals
- Hidden 'Jumping Gene' Variant Linked to Higher Pancreatic Cancer Risk
- Common White Blood Cells Produce Schizophrenia-Linked Protein
- Nanopore Method Captures RNA Folding at Single-Molecule Resolution
- Tumor Microenvironment Marker Linked to Worse Survival in Solid Tumors
Channels
Clinical Chemistry
view channel
New Machine-Learning Equation Improves LDL Cholesterol Assessment
Accurate assessment of low-density lipoprotein (LDL) cholesterol is central to cardiovascular risk management, yet calculation methods can underestimate values in some patients. Laboratories widely use... Read more
Blood Biomarker May Signal Cognitive Decline Risk a Decade Before Symptoms
Accurately identifying which cognitively healthy older adults will later develop impairment due to Alzheimer’s disease remains difficult, as brain scans and genetic testing provide only part of the risk picture.... Read moreMolecular Diagnostics
view channel
Multiplex PCR Test Differentiates Four Causes of Ulcerative Skin Lesions
Vesicular and pustular skin lesions can stem from multiple viral pathogens, complicating timely diagnosis and management. Sequential single-pathogen testing can miss infections when the causative agent... Read more
Blood Test Guides Patient Selection for Radiopharmaceutical Therapy in Prostate Cancer
Radium-223 dichloride is a bone-targeted radiopharmaceutical therapy that improves overall survival and quality of life for many patients with metastatic castration-resistant prostate cancer (mCRPC), but... Read moreHematology
view channel
New Marker Helps Detect Aggressive Multiple Myeloma Earlier
Multiple myeloma is an incurable malignancy of plasma cells and the second most common blood cancer worldwide, with more than 188,000 new cases each year. Although therapies have advanced, most patients... Read more
New Biomarkers Predict Resistance to Targeted Therapy in Rare Blood Cancer
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive leukemia with limited treatment options and a poor prognosis. Although tagraxofusp is the first approved targeted therapy for... Read moreImmunology
view channel
Ultrasensitive Blood Test Detects Sjögren’s Signature Years Before Diagnosis
Sjögren’s disease is a common autoimmune condition that can be difficult to recognize early, leading to delayed diagnosis and persistent symptom burden. It affects around half a million people in the UK... Read more
New Assays Expand Cytokine Testing for Transplant and Immunocompromised Patients
Eurofins Viracor has introduced three plasma-based assays—CXCL9 (Test Code 33607), CXCL10 (Test Code 33609), and interleukin-18 (IL-18) (Test Code 33611)—expanding its immunology testing menu for transplant... Read moreMicrobiology
view channel
Syndromic GI Panel Detects Cyclospora for Rapid Case Confirmation
U.S. health authorities have reported a rapid increase in cyclosporiasis since May 2026, with more than 1,600 confirmed infections and thousands of additional suspected cases under investigation.... Read more
Rapid Panel Identifies Gram-Negative Pathogens and Resistance Markers in Bloodstream Infections
Bloodstream infections require rapid identification of causative pathogens and resistance mechanisms to guide effective therapy. Delays in profiling gram-negative organisms, which are frequently associated... Read morePathology
view channel
Digital Pathology Tool Predicts Breast Cancer Outcomes and Therapy Response
Breast cancer prognosis often depends on microscopic assessment of tumor architecture, a process that can be subjective and lead to variable predictions across patient groups. Quantitative measures that... Read more
AI Bone Marrow Mapping Provides New Tool to Track Blood Cancer Severity
Myelodysplastic neoplasms, a group of blood cancers that primarily affect older adults, are challenging to stage and monitor, often requiring repeated bone marrow biopsies that can yield uncertain interpretations.... Read moreTechnology
view channel
Training Device Improves Accuracy of Pooled Molecular Diagnostics
High-throughput molecular diagnostics have transformed infectious disease detection, but many workflows remain difficult to execute accurately without extensive training. Sample pooling can cut per‑test... Read more
New CE-Certified Software Advances Whole-Genome Cancer Testing
European hospitals are increasingly using comprehensive tumor genomics to guide therapy, but routine whole genome sequencing (WGS) requires validated, regulation-compliant workflows. A newly CE-certified... Read more
National Rare Disease Registry Standardizes Genetic and Clinical Data for Coordinated Care
Rare diseases collectively impose a significant clinical burden despite their individual rarity, often involving multisystem presentations and prolonged diagnostic journeys. Limited specialist expertise... Read moreIndustry
view channel
Tempus to Acquire Personalis in $1.5 Billion Precision Oncology Deal
Tempus AI, Inc. (Chicago, IL, USA) has entered into a definitive agreement to acquire Personalis, Inc. (Fremont, CA, USA), expanding its capabilities in molecular residual disease (MRD) testing and cancer... Read more




 Assay.jpg)



